Literature DB >> 27923832

ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Tiansuo Zhao1,2, Wenna Jiang1, Xiuchao Wang1, Hongwei Wang1, Chen Zheng1, Yang Li1, Yan Sun3, Chongbiao Huang1, Zhi-Bo Han4, Shengyu Yang5, Zhiliang Jia2, Keping Xie6, He Ren1, Jihui Hao7.   

Abstract

The ETS family transcription factor ESE3 is a crucial element in differentiation and development programs for many epithelial tissues. Here we report its role as a tumor suppressor in pancreatic cancer. We observed drastically lower ESE3 expression in pancreatic ductal adenocarcinomas (PDAC) compared with adjacent normal pancreatic tissue. Reduced expression of ESE3 in PDAC correlated closely with an increase in lymph node metastasis and vessel invasion and a decrease in relapse-free and overall survival in patients. In functional experiments, downregulating the expression of ESE3 promoted PDAC cell motility and invasiveness along with metastasis in an orthotopic mouse model. Mechanistic studies in PDAC cell lines, the orthotopic mouse model, and human PDAC specimens demonstrated that ESE3 inhibited PDAC metastasis by directly upregulating E-cadherin expression at the level of its transcription. Collectively, our results establish ESE3 as a negative regulator of PDAC progression and metastasis by enforcing E-cadherin upregulation. Cancer Res; 77(4); 874-85. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27923832      PMCID: PMC5313376          DOI: 10.1158/0008-5472.CAN-16-2170

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines.

Authors:  A Menke; C Philippi; R Vogelmann; B Seidel; M P Lutz; G Adler; D Wedlich
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 2.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

3.  ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.

Authors:  Domenico Albino; Nicole Longoni; Laura Curti; Maurizia Mello-Grand; Sandra Pinton; Gianluca Civenni; George Thalmann; Gioacchino D'Ambrosio; Manuela Sarti; Fausto Sessa; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

4.  N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer.

Authors:  Y Su; J Li; A K Witkiewicz; D Brennan; T Neill; J Talarico; G L Radice
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

5.  LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer.

Authors:  Tiansuo Zhao; He Ren; Jing Li; Jing Chen; Huan Zhang; Wen Xin; Yan Sun; Lei Sun; Yongwei Yang; Junwei Sun; Xiuchao Wang; Song Gao; Chongbiao Huang; Huafeng Zhang; Shengyu Yang; Jihui Hao
Journal:  Cancer Res       Date:  2014-11-10       Impact factor: 12.701

6.  The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.

Authors:  Kun Guo; Jiujie Cui; Ming Quan; Dacheng Xie; Zhiliang Jia; Daoyan Wei; Liang Wang; Yong Gao; Qingyong Ma; Keping Xie
Journal:  Clin Cancer Res       Date:  2016-07-22       Impact factor: 12.531

7.  KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis.

Authors:  Daoyan Wei; Liang Wang; Yongmin Yan; Zhiliang Jia; Mihai Gagea; Zhiwei Li; Xiangsheng Zuo; Xiangyu Kong; Suyun Huang; Keping Xie
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

8.  Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.

Authors:  R Cangemi; A Mensah; V Albertini; A Jain; M Mello-Grand; G Chiorino; C V Catapano; G M Carbone
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

9.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01

10.  Common activation of canonical Wnt signaling in pancreatic adenocarcinoma.

Authors:  Marina Pasca di Magliano; Andrew V Biankin; Patrick W Heiser; David A Cano; Pedro J A Gutierrez; Therese Deramaudt; Davendra Segara; Amanda C Dawson; James G Kench; Susan M Henshall; Robert L Sutherland; Andrzej Dlugosz; Anil K Rustgi; Matthias Hebrok
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

View more
  17 in total

1.  Fms related tyrosine kinase 1 (Flt1) functions as an oncogene and regulates glioblastoma cell metastasis by regulating sonic hedgehog signaling.

Authors:  Kun Jiang; Yan-Ping Wang; Xiao-Dong Wang; Xiao-Bo Hui; Lian-Shu Ding; Ji Liu; Dai Liu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

2.  Automated platform for cell selection and separation based on four-dimensional motility and matrix degradation.

Authors:  Hannah L Nowotarski; Peter J Attayek; Nancy L Allbritton
Journal:  Analyst       Date:  2020-02-21       Impact factor: 4.616

3.  Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma.

Authors:  Dingyuan Hu; Daniel Ansari; Krzysztof Pawłowski; Qimin Zhou; Agata Sasor; Charlotte Welinder; Theresa Kristl; Monika Bauden; Melinda Rezeli; Yi Jiang; György Marko-Varga; Roland Andersson
Journal:  Oncotarget       Date:  2018-01-03

4.  A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma.

Authors:  Courtney W Houchen; Min Li
Journal:  BMC Med       Date:  2020-06-29       Impact factor: 8.775

5.  Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.

Authors:  Jing Liu; Wenna Jiang; Kaili Zhao; Hongwei Wang; Tianxing Zhou; Weiwei Bai; Xiuchao Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Tai Qin; Wenwen Yu; Bo Yang; Xin Li; Danqi Fu; Wei Tan; Shengyu Yang; He Ren; Jihui Hao
Journal:  J Exp Med       Date:  2019-02-07       Impact factor: 14.307

6.  Blockage of ETS homologous factor inhibits the proliferation and invasion of gastric cancer cells through the c-Met pathway.

Authors:  Meng-Li Gu; Xin-Xin Zhou; Meng-Ting Ren; Ke-Da Shi; Mo-Sang Yu; Wen-Rui Jiao; Ya-Mei Wang; Wei-Xiang Zhong; Feng Ji
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

7.  ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.

Authors:  Tianxing Zhou; Jing Liu; Yongjie Xie; Shuai Yuan; Yu Guo; Weiwei Bai; Kaili Zhao; Wenna Jiang; Hongwei Wang; Haotian Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Xiuchao Wang; Shengyu Yang; Jihui Hao
Journal:  Gut       Date:  2021-03-05       Impact factor: 31.793

Review 8.  ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.

Authors:  Ian Y Luk; Camilla M Reehorst; John M Mariadason
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

9.  IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.

Authors:  Tiansuo Zhao; Fanjie Jin; Di Xiao; Hongwei Wang; Chongbiao Huang; Xiuchao Wang; Song Gao; Jing Liu; Shengyu Yang; Jihui Hao
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

10.  Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.

Authors:  Fanjie Jin; Di Xiao; Tiansuo Zhao; Ming Yu
Journal:  Oncol Lett       Date:  2019-11-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.